Medical Oncology

Annals of Oncology Journal Club

Questions discussed in this category

Would you consider adding adjuvant ribociclib for a patient who has already received 2 years of endocrine therapy and is eligible for ribociclib according to the NATALEE trial?

6 Answers available

How do you modify your adjuvant therapy course in a patient experiencing liver dysfunction within the first few months of starting CDK4/6i?

For a patient recently started on therapy who develops severe transaminitis (AST and ALT >10–15× ULN) which does not readily improve in...

1 Answer available

Papers discussed in this category

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Oct 21

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025 Sep 17

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.

J. Clin. Oncol., 2020 Sep 20

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

Lancet (London, England), 2020 Mar 07

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.

JAMA oncology, 2023 Sep 01

Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.

Nature, 2024 Nov 27

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.

Related Topics in Medical Oncology